Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "Melatonin synthesis pathway enzymes" refers collectively to the set of enzymes responsible for the stepwise conversion of tryptophan into melatonin, primarily within the pineal gland. The canonical sequence in mammals involves: 1. Tryptophan hydroxylase – catalyzes hydroxylation of L‑tryptophan to 5-hydroxy-L‑tryptophan. 2. Aromatic L-amino acid decarboxylase – converts 5-hydroxy-L‑tryptophan into serotonin. 3. Serotonin N-acetyltransferase (also known as aralkylamine N-acetyltransferase, AANAT) – acetylates serotonin to form N-acetylserotonin; this is considered the rate-limiting step and is tightly regulated by circadian signals[1][2][3][4]. 4. Acetylserotonin O-methyltransferase (also known as ASMT or hydroxyindole-O-methyltransferase, HIOMT) – methylates N-acetylserotonin to produce melatonin[2][3]. These enzymes are essential for maintaining normal sleep patterns and circadian rhythms through their regulation by neural and hormonal signals such as norepinephrine acting via adrenergic receptors on pinealocytes[4]. Abnormalities in these enzymatic steps have been linked with various medical conditions including sleep disturbances, psychiatric illnesses like depression, and metabolic syndromes such as diabetes[3]. Note that "Melatonin synthesis pathway enzymes" is not a single molecular entity but rather a functional group comprising several distinct proteins—each with its own gene/protein name—and thus does not conform to standard naming conventions for drug targets. Because this entry refers collectively to multiple proteins rather than one specific molecule/receptor, it should be flagged as an incorrect target designation if strict specificity is required. The main mammalian enzymes involved are tryptophan hydroxylase, aromatic L-amino acid decarboxylase, aralkylamine N-acetyltransferase (AANAT), and acetylserotonin O-methyltransferase (ASMT/HIOMT)[1][2][3].
Inhibition or activation of enzymatic steps in melatonin biosynthesis can alter endogenous melatonin production and downstream physiological effects[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Melatonin synthesis pathway enzyme (null).